Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 12,225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Type 1 Diabetes
Interventions: Type 1 Doing Well (T1DW) Program, Diabetes-Related Information and Resources Program; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Fingolimod, Disease Modifying therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 122
States / cities: Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more

Conditions: Multiple Myeloma
Interventions: CART-19 cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, Gait Disorders, Neurologic
Interventions: Ekso GT™ exoskeleton; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Venous Thromboembolism, Multiple Myeloma
Interventions: Apixaban; Drug
Lead sponsor: Gregory Piazza; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC, Modified Paleolithic Elimination diet, Time Restricted Olive Oil Based (TROO) Ketogenic Diet, Usual diet with Dietary Guidelines for Americans Diet information; Dietary Supplement · Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Connective Tissue Disease, Dissecting Aneurysm, Ehlers Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Placebo, ATYR1940; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Rochester, New York • Columbus, Ohio

Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: BL-8040, Leukapheresis, Hematopoietic cell transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • St Louis, Missouri • Columbus, Ohio

Conditions: Hemoglobinuria, Paroxysmal
Interventions: Eculizumab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia
Interventions: AZD3480; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 66
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 63 more

Conditions: Hypertriglyceridemia
Interventions: rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 21
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more

Conditions: Early Stage Parkinson's Disease
Interventions: Aplindore, Placebo; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diffuse Large B Cell Lymphoma
Interventions: IMO-8400; Drug
Lead sponsor: Idera Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more

Conditions: Peri-Implantitis
Interventions: 2.5 mg Chlorhexidine gluconate chip; Drug
Lead sponsor: Dexcel Pharma Technologies Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Tivozanib, Sunitinib; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Los Angeles, California • Albany, Georgia • Atlanta, Georgia + 12 more

Conditions: Hearing Loss, Sensorineural, Cochlear Implant, Cochlear Implant Recipients, Hearing Disorders, Cochlear Implants
Interventions: MED-EL Remote Care; Device
Lead sponsor: Med-El Corporation; Industry
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Ann Arbor, Michigan • Chapel Hill, North Carolina

Conditions: Obstructive Sleep Apnea, Sleep Apnea
Interventions: ProSomnus® EVO Sleep and Snore Device; Device
Lead sponsor: ProSomnus Sleep Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Redwood City, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Immune System Disorder (Healthy Volunteer)
Interventions: Belumosudil mesylate, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease
Interventions: PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 12
States / cities: Sun City, Arizona • Fresno, California • San Diego, California + 9 more

Conditions: Infertility, Pregnancy Outcome, Live Birth, In Vitro Fertilization
Interventions: 10% SSS embryo culture medium protein supplementation, 0.5% HSA embryo culture medium protein supplementation; Other
Lead sponsor: Texas Health Resources; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Multiple Sclerosis
Interventions: Low-fat diet; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Influenza
Interventions: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more

Search by objective public record fields.

EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

CART-19 Post-ASCT for Multiple Myeloma

Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Efficacy of Diet on Quality of Life in Multiple Sclerosis

Study of Heritable Connective Tissue Disorders

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

MED-EL Remote Care Multi-Center Feasibility Study

Severe OSA Study (SOS)

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

in Vitro Fertilization (IVF) Media Protein and Live Birth Rates

Low Fat Diet for Fatigue in MS

Reverse Genetic H9N2 Influenza Vaccine Study in Adults